Find out more about Michael Michael's experience
Michael Michael's highlights
FEATURED Journal article
The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (F-18) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumorsRead more
Michael Michael's selected work
Targeted Characterization Of Therapeutic Resistance Mechanisms In Colorectal Cancer Using ..
Prognostic factors influencing survival in patients undergoing cytoreductive surgery with ..
Mechanisms Of Resistance To Immunological Targeting Of Primary And Metastatic Colorectal C..
Mapping Patterns Of Care For People With Pancreatic Cancer: How Close Are We To The Optima..
Displaying the 10 most recent projects by Michael Michael.
Topgear: Trial Of Preoperative Therapy For Gastric And Esophagogastric Junction Adenocarcinoma. A Randomised Phase Til Trial Of Preoperative Chemoradiotherapy Versus Preoperative Chemotherapy For Resectable Gastric Cancer
While surgery to remove gastric (stomach) cancer has been traditionally accepted as the only way to potentially cure the disease, there have..
Displaying the 174 most recent scholarly works by Michael Michael.
The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (F-18) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors
Mei Sim Lung, Rodney J Hicks, Nick Pavlakis, Emma Link, Michael Jefford, Benjamin Thomson, David K Wyld, Winston Liauw, Timothy Akhurst, Narmatha Kuru, Michael Michael
Journal article | 2020 | Asia-Pacific Journal of Clinical Oncology
AIMS: This multicenter phase II trial evaluates the efficacy of everolimus in poor prognosis grade 2 (G2) pancreatic neuroendocrin..
Prognostic factors influencing survival in patients undergoing cytoreductive surgery with HIPEC for isolated colorectal peritoneal metastases: A systematic review and meta-analysis.
Vignesh Narasimhan, Sabrina Tan, Joseph Kong, Toan Pham, Michael Michael, Robert Ramsay, Satish Warrier, Alexander Heriot
Journal article | 2020 | Colorectal Disease
BACKGROUND AND AIMS: Peritoneal metastases from colorectal cancer confer the worst survival among all sites of metastases. The ado..
Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?
Vignesh Narasimhan, Francis Cheung, Peadar Waters, Oliver Peacock, Satish Warrier, Craig Lynch, Michael Michael, Robert Ramsay, Alexander Heriot
Journal article | 2019 | The Surgeon
BACKGROUND AND OBJECTIVES: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers selected pati..
First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427).
Toan Pham, Lloyd Pereira, Sara Roth, Laura Galletta, Emma Link, Tim Akhurst, Ben Solomon, Michael Michael, Phillip Darcy, Shienny Sampurno, Alexander Heriot, Robert Ramsay, Jayesh Desai
Journal article | 2019 | Contemporary Clinical Trials Communications
Background: MYB is a transcription factor that is overexpressed in colorectal cancer (CRC) and also a driver mutation in adenoid c..
Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention
Lisa Guccione, Karla Gough, Allison Drosdowsky, Krista Fisher, Timothy Price, Nick Pavlakis, Mustafa Khasraw, David Wyld, David Ransom, Grace Kong, Megan Rogers, Simone Leyden, John Leyden, Michael Michael, Penelope Schofield
Journal article | 2019 | JMIR Research Protocols
Perceptions in the management of colorectal peritoneal metastases: A bi-national survey of colorectal surgeons
Vignesh Narasimhan, Satish Warrier, Michael Michael, Jacob J McCormick, Robert Ramsay, Craig Lynch, Alexander Heriot
Journal article | 2019 | Pleura and Peritoneum
Background: There is great variability in the uptake of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy..
Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study.
Vignesh Narasimhan, Satish Warrier, Michael Michael, Robert Ramsay, Alexander Heriot
Journal article | 2019 | Journal of Gastrointestinal Surgery
BACKGROUND AND OBJECTIVES: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can offer selected p..
The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma
Grace Kong, Tess Schenberg, Christopher J Yates, Alison Trainer, Nirupa Sachithanandan, Amir Iravani, Aravind Ravi Kumar, Michael S Hofman, Tim Akhurst, Michael Michael, Rodney J Hicks
Journal article | 2019 | The Journal of Clinical Endocrinology & Metabolism
Purpose: Germline succinate dehydrogenase (SDHx) mutation carriers, especially SDHB, are at increased risk for malignancy and requ..
Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience
Vignesh Narasimhan, Maneka Britto, Pham Toan, Satish Warrier, Arun Naik, A Craig Lynch, Michael Michael, Jeanne Tie, Robert Ramsay, Alexander Heriot
Journal article | 2019 | Diseases of the Colon & Rectum
BACKGROUND: Colorectal cancer is the second leading cause of cancer-related mortality worldwide. Peritoneal metastases carry the w..
Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care
Braden Woodhouse, Sharon Pattison, Eva Segelov, Simron Singh, Kate Parker, Grace Kong, William Macdonald, David Wyld, Goswin Meyer-Rochow, Nick Pavlakis, Siobhan Conroy, Vallerie Gordon, Jonathan Koea, Nicole Kramer, Michael Michael, Kate Wakelin, Tehmina Asif, Dorothy Lo, Timothy Price, Ben Lawrence, et al.
Journal article | 2019 | Journal of Clinical Medicine
Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms
Vignesh Narasimhan, Pham Toan, Satish Warrier, A Craig Lynch, Michael Michael, Jeanne Tie, Robert Ramsay, Alexander Heriot
Journal article | 2019 | ANZ Journal of Surgery
BACKGROUND: Appendiceal epithelial neoplasms are rare cancers. Management of peritoneal disease from appendiceal neoplasms has his..
The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers
Ashika D Maharaj, Jennifer F Holland, Ri O Scarborough, Sue M Evans, Liane J Ioannou, Wendy Brown, Daniel G Croagh, Charles HC Pilgrim, James G Kench, Lara R Lipton, Trevor Leong, John J McNeil, Mehrdad Nikfarjam, Ahmad Aly, Paul R Burton, Paul A Cashin, Julie Chu, Cuong P Duong, Peter Evans, David Goldstein, et al.
Journal article | 2019 | BMJ Open
PURPOSE: The Upper Gastrointestinal Cancer Registry (UGICR) was developed to monitor and improve the quality of care provided to p..
Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases
Vignesh Narasimhan, Atandrila Das, Satish Warrier, Craig Lynch, Jacob McCormick, Jeanne Tie, Michael Michael, Robert Ramsay, Alexander Heriot
Journal article | 2019 | Langenbeck's Archives of Surgery
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series
Isaac Goncalves, Kate Burbury, Michael Michael, Amir Iravani, Aravind S Ravi Kumar, Tim Akhurst, Ing S Tiong, Piers Blombery, Michael S Hofman, David Westerman, Rodney J Hicks, Grace Kong
Journal article | 2019 | European Journal of Nuclear Medicine and Molecular Imaging
Colorectal peritoneal metastases: Exploring the immune landscape and the potential of immunotherapy using organoid models
Vignesh Narasimhan, Pham Toan, Kasmira Wilson, Susan Woods, Daniel Worthley, Jeanne Tie, Michael Michael, Alexander Heriot, Robert Ramsay
Conference Proceedings | 2019 | Immunology
Early Outcomes of Surgery for Carcinoid Heart Disease.
Matthew S Yong, Grace Kong, Prakash Ludhani, Michael Michael, John Morgan, Michael S Hofman, Rodney J Hicks, Marco Larobina
Journal article | 2019 | Heart, Lung and Circulation
BACKGROUND: The prognosis of patients with metastatic neuroendocrine neoplasms (NEN) continues to improve with modern oncological ..
Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.
Michael Michael, Rachel Wong, Sanjeev Singh Gill, David Goldstein, Sam Ngan, Alexander Graham Heriot, Emma Link, Maria Farrell, Paul J Neeson, Robert George Ramsay, Kasmira Wilson, Catherine Mitchell, Jeanne Tie, Nick Pavlakis, John Raymond Zalcberg, Eva Segelov
Conference Proceedings | 2019 | Journal of Clinical Oncology
A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.
Oliver Klein, Damien Kee, Ben Markman, Rachael Chang Lee, Michael Michael, Linda R Mileshkin, Clare L Scott, Richelle Linklater, Sid Menon, Niall C Tebbutt, Jodie Palmer, Andreas Behren, Jonathan S Cebon
Conference Proceedings | 2019 | Journal of Clinical Oncology
Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.
Vignesh Narasimhan, Kasmira Wilson, Maneka Britto, Satish Warrier, A Craig Lynch, Michael Michael, Jeanne Tie, Tim Akhurst, Catherine Mitchell, Robert Ramsay, Alexander Heriot
Journal article | 2019 | Journal of Gastrointestinal Surgery
BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare clinical presentation, with considerable morbidity and mortality if left untrea..
Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)
Grace Kong, Simona Grozinsky-Glasberg, Michael S Hofman, Tim Akhurst, Amichay Meirovitz, Ofra Maimon, Yodphat Krausz, Jeremy Godefroy, Michael Michael, David J Gross, Rodney J Hicks
Journal article | 2019 | European Journal of Nuclear Medicine and Molecular Imaging
A clinical trial with protracted infusion 5-fluorouracil and mitomycin C for localized squamous cell carcinoma of the anus
David Ngan, Julie Chu, Sarat Chander, Michael Michael, Alexander G Heriot, Samuel Y Ngan, Danny Rischin, Trevor Leong
Journal article | 2019 | Asia-Pacific Journal of Clinical Oncology
Characteristics and Outcomes of Therapy-Related Myeloid Neoplasms after Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Neoplasm (NEN): A Single Centre Series
I Goncalves, K Burbury, D Westerman, P Blombery, IS Tiong, A Iravani, A Ravikumar, M Michael, M Hofman, T Akhurst, R Hicks, G Kong
Conference Proceedings | 2019 | NEUROENDOCRINOLOGY
Tumor-Infiltrating Lymphocyte Function Predicts Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Joseph Cherng Huei Kong, Glen Robert Guerra, Rosemary Magdalena Millen, Sara Roth, Huiling Xu, Paul Joseph Neeson, Phillip Kevin Darcy, Michael Henry Kershaw, Shienny Sampurno, Jordane Malaterre, David Shi Hao Liu, Duc Pham Toan, Vignesh Narasimhan, Minyu Wang, Yu-Kuan Huang, Kumar Visvanathan, Jacob McCormick, Andrew Craig Lynch, Satish Warrier, Michael Michael, et al.
Journal article | 2018 | JCO Precision Oncology
Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood
Z Liu, J Martin, L Orme, B Seddon, J Desai, W Nicholls, D Thomson, D Porter, G McCowage, C Underhill, N Cranswick, M Michael, M Zacharin, A Herschtal, J Sivasuthan, DM Thomas
Journal article | 2018 | Cancer Chemotherapy and Pharmacology
Optical barcoding highlights novel characteristics of treatment resistant cells in metastatic colorectal cancer
Frederic Hollande, Corina Behrenbruch, Carolyn Shembrey, Pu Xue Qiao, Davide Ferrari, Benjamin Thomson, Michael Michael, Alexander Heriot
Conference Proceedings | 2018 | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors
Simron Singh, Lesley Moody, David L Chan, David C Metz, Jonathan Strosberg, Timothy Asmis, Dale L Bailey, Emily Bergsland, Kari Brendtro, Richard Carroll, Sean Cleary, Michelle Kim, Grace Kong, Calvin Law, Ben Lawrence, Alexander McEwan, Caitlin McGregor, Michael Michael, Janice Pasieka, Nick Pavlakis, et al.
Journal article | 2018 | JAMA Oncology
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM (TM) system in a quaternary oncology centre
Michael Moloney, David Faulkner, Emma Link, Danny Rischin, Ben Solomon, Annette M Lim, John R Zalcberg, Michael Jefford, Michael Michael
Journal article | 2018 | Cancer Chemotherapy and Pharmacology
Induction PRRT With CAPTEM Chemotherapy in a High-risk Population of Metastatic Neuroendocrine Neoplasia (NEN): Balancing Efficacy With Risk
AS Ravi Kumar, J Ferdinandus, J Callahan, T Akhurst, MS Hofman, A Iravani, G Kong, M Michael, RJ Hicks
Conference Proceedings | 2018 | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey
John Leyden, Nick Pavlakis, David Chan, Michael Michael, Stephen Clarke, Mustafa Khasraw, Timothy Price
Journal article | 2018 | Asia-Pacific Journal of Clinical Oncology
Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process
Corina Behrenbruch, Carolyn Shembrey, Sophie Paquet-Fifield, Christina Molck, Hyun-Jung Cho, Michael Michael, Benjamin NJ Thomson, Alexander G Heriot, Frederic Hollande
Journal article | 2018 | Clinical & Experimental Metastasis
Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis
Sue Ping Thang, Mei Sim Lung, Grace Kong, Michael S Hofman, Jason Callahan, Michael Michael, Rodney J Hicks
Journal article | 2018 | European Journal of Nuclear Medicine and Molecular Imaging
AGITG nabnec: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.
Lorraine A Chantrill, Lara Rachel Lipton, Michael Hofman, Val Gebski, Anthony Gill, Ben Markman, Sonia Yip, Christos Stelios Karapetis, Nick Pavlakis, Shu Fen Wong, David Turner Ransom, Katrin Marie Sjoquist, Adnan Nagrial, Michael Michael, Uzma Rayani, Martinus Oostendorp, John Simes, Mustafa Khasraw
Conference Proceedings | 2018 | Journal of Clinical Oncology
Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumor: Preliminary Baseline Characteristics from the Nutrition in NETs Study
E Kennedy, N Kiss, M Michael, K Gough, A Drosdowsky, M Krishnasamy
Conference Proceedings | 2018 | NEUROENDOCRINOLOGY
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG
Trevor Leong, B Mark Smithers, Karin Haustermans, Michael Michael, Val Gebski, Danielle Miller, John Zalcberg, Alex Boussioutas, Michael Findlay, Rachel L O'Connell, Jaclyn Verghis, David Willis, Tomas Kron, Melissa Crain, William K Murray, Florian Lordick, Carol Swallow, Gail Darling, John Simes, Rebecca Wong
Journal article | 2017 | Annals of Surgical Oncology
Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases.
J Zhao, KMC van Mierlo, J Gómez-Ramírez, H Kim, CHC Pilgrim, P Pessaux, SS Rensen, EP van der Stok, FG Schaap, O Soubrane, T Takamoto, L Viganò, B Winkens, CHC Dejong, SWM Olde Damink, undefined Chemotherapy-Associated Liver Injury (CALI) consortium
Journal article | 2017 | British Journal of Surgery
BACKGROUND: The impact of chemotherapy-associated liver injury (CALI) on postoperative outcome in patients undergoing partial hepa..
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study
Brian G Czito, Dustin A Deming, Gayle S Jameson, Mary F Mulcahy, Houman Vaghefi, Matthew W Dudley, Kyle D Holen, Angela DeLuca, Rajendar K Mittapalli, Wijith Munasinghe, Lei He, John R Zalcberg, Samuel Y Ngan, Philip Komarnitsky, Michael Michael
Journal article | 2017 | The Lancet Gastroenterology & Hepatology
The utility of genomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynannics: The PREDICT IR study.
Michael Michael, Winston Liauw, Sue-Anne McLachlan, Emma Link, Anetta Matera, Mick Thompson, Michael Jefford, Rodney J Hicks, Carleen Cullinane, Ian Campbell, Philip James Beale, Christos Stelios Karapetis, Timothy Price, Matthew E Burge
Conference Proceedings | 2017 | Journal of Clinical Oncology
High clinical and morphologic response using Y-90-DOTA-octreotate sequenced with Lu-177-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours
Grace Kong, Jason Callahan, Michael S Hofman, David A Pattison, Tim Akhurst, Michael Michael, Peter Eu, Rodney J Hicks
Journal article | 2017 | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Relative Value of Restaging MRI, CT, and FDG-PET Scan After Preoperative Chemoradiation for Rectal Cancer
Daniel A Schneider, Timothy J Akhurst, Samuel Y Ngan, Satish K Warrier, Michael Michael, Andrew C Lynch, Luc Te Marvelde, Alexander G Heriot
Journal article | 2016 | Diseases of the Colon & Rectum
Alex Boussioutas, Stephen Fox, Iris Nagtegaal, Alexander Heriot, Jonathan Knowles, Michael Michael, Sam Ngan, Kathryn Field, John Zalcberg
Book Chapter | 2016
This chapter covers colorectal cancer, and includes information on epidemiology, risk factors (chronic inflammation/inflammatory b..
TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
Trevor Leong, B Mark Smithers, Michael Michael, Val Gebski, Alex Boussioutas, Danielle Miller, John Simes, John Zalcberg, Karin Haustermans, Florian Lordick, Christoph Schuhmacher, Carol Swallow, Gail Darling, Rebecca Wong
Journal article | 2015 | BMC Cancer
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC
Michael Michael, Shane C White, Ehtesham Abdi, Louise Nott, Phillip Clingan, Allan Zimet, Peter Button, Daniel Gregory, Benjamin Solomon, Alexander Dobrovic, Hongdo Do, Stephen Clarke
Journal article | 2015 | Asia-Pacific Journal of Clinical Oncology
Favourable outcomes of Lu-177-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
Raghava Kashyap, Michael S Hofman, Michael Michael, Grace Kong, Timothy Akhurst, Peter Eu, Diana Zannino, Rodney J Hicks
Journal article | 2015 | European Journal of Nuclear Medicine and Molecular Imaging
Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer
M Michael, S Chander, J McKendrick, JR MacKay, M Steel, R Hicks, A Heriot, T Leong, P Cooray, M Jefford, J Zalcberg, M Bressel, B McClure, SY Ngan
Journal article | 2014 | British Journal of Cancer
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
G Kong, M Thompson, M Collins, A Herschtal, MS Hofman, V Johnston, P Eu, M Michael, Rodney J Hicks
Journal article | 2014 | European Journal of Nuclear Medicine and Molecular Imaging
Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors
Stephen J Clarke, Christos S Karapetis, Peter Gibbs, Nick Pavlakis, Jayesh Desai, Michael Michael, Niall C Tebbutt, Tim J Price, Josep Tabernero
Journal article | 2013 | Critical Reviews in Oncology Hematology
Individualisation of the systemic biologic therapy for advanced colorectal cancer: Light beyond K-ras status
S Ananda, M Michael
Book Chapter | 2012 | International Journal of Cancer Prevention
Metastatic colorectal cancer (CRC) is one of the most common malignancies in the Western world. The number of active anti-cancer a..
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer
M Michael, N Pavlakis, P Clingan, R De Boer, M Johnston, S Clarke
Journal article | 2012 | Oncology Reports
Twenty-Five-Year Experience With Radical Chemoradiation for Anal Cancer
Jonathan M Tomaszewski, Emma Link, Trevor Leong, Alexander Heriot, Melisa Vazquez, Sarat Chander, Julie Chu, Marcus Foo, Mark T Lee, Craig A Lynch, John Mackay, Michael Michael, Phillip Tran, Samuel Y Ngan
Journal article | 2012 | International Journal of Radiation: Oncology - Biology - Physics
Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidity
Charles HC Pilgrim, Laveniya Satgunaseelan, Alan Pham, William Murray, Emma Link, Marty Smith, Val Usatoff, Peter M Evans, Simon Banting, Benjamin N Thomson, Wayne A Phillips, Michael Michael
Journal article | 2012 | HPB: the official journal of the IHPBA
Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C-14-erythromycin breath test and the antipyrine clearance test
M Michael, C Cullinane, A Hatzimihalis, C O'Kane, A Milner, R Booth, S Schlicht, SJ Clarke, P Francis
Journal article | 2012 | Cancer Chemotherapy and Pharmacology
Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?
Linda Mileshkin, Bhaumik Shah, Michael Michael
Journal article | 2012 | Chemotherapy Research and Practice
There have been many exciting new breakthroughs in understanding tumour biology. This has opened up the possibility of personalize..
MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
Jochen K Lennerz, Eunice L Kwak, Allison Ackerman, Michael Michael, Stephen B Fox, Kristin Bergethon, Gregory Y Lauwers, James G Christensen, Keith D Wilner, Daniel A Haber, Ravi Salgia, Yung-Jue Bang, Jeffrey W Clark, Benjamin J Solomon, A John Iafrate
Journal article | 2011 | Journal of Clinical Oncology
A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative Therapy Trans Tasman Radiation Oncology Study TROG 03.07
Bryan H Burmeister, Michael Michael, Elizabeth Burmeister, Sharon Cox, Margot Lehman, Andrew Wirth, Keith Horwood, Giuseppe Sasso, Barham Forouzesh, David Ball
Journal article | 2011 | Journal of Thoracic Oncology
ADJUVANT CHEMORADIATION FOR GASTRIC CANCER USING EPIRUBICIN, CISPLATIN, AND 5-FLUOROURACIL BEFORE AND AFTER THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY WITH CONCURRENT INFUSIONAL 5-FLUOROURACIL: A MULTICENTER STUDY OF THE TRANS-TASMAN RADIATION ONCOLOGY GROUP
Trevor Leong, Daryl Lim Joon, David Willis, Jayasingham Jayamoham, Nigel Spry, Jennifer Harvey, Juliana Di Iulio, Alvin Milner, G Bruce Mann, Michael Michael
Journal article | 2011 | International Journal of Radiation: Oncology - Biology - Physics
miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.
Cameron M Smith, David I Watson, Mary P Leong, George C Mayne, Michael Z Michael, Bas PL Wijnhoven, Damian J Hussey
Journal article | 2011 | World Journal of Gastroenterology
AIM: To investigate miR-200 family expression in Barrett's epithelium, gastric and duodenal epithelia, and esophageal adenocarcino..
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
M Michael, G Vlahovic, K Khamly, KJ Pierce, F Guo, AJ Olszanski
Journal article | 2010 | British Journal of Cancer
BACKGROUND: Tumoural interstitial hypertension, possibly modulated by platelet-derived and vascular endothelial growth factor rece..
Lu-177-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity In-111-octreotide
Daniel Hubble, Grace Kong, Michael Michael, Val Johnson, Shakher Ramdave, Rodney John Hicks
Journal article | 2010 | European Journal of Nuclear Medicine and Molecular Imaging
The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy.
Christine Carrington, Leanne Stone, Bogda Koczwara, Christina Searle, Jim Siderov, Ben Stevenson, Michael Michael, Susan Hyde, Angela Booth, Shelley Rushton, undefined Clinical Oncological Society of Australia
Journal article | 2010 | Asia-Pacific Journal of Clinical Oncology
The issue of medication safety is highly significant when anti-cancer therapy is used as a treatment modality due to the high pote..
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
E Van Cutsem, F Rivera, S Berry, A Kretzschmar, M Michael, M DiBartolomeo, M-A Mazier, J-L Canon, V Georgoulias, M Peeters, J Bridgewater, D Cunningham, undefined First BEAT investigators
Journal article | 2009 | Annals of Oncology
BACKGROUND: Bevacizumab significantly improves survival when added to chemotherapy for metastatic colorectal cancer (mCRC). The Be..
LOCAL CONTROL AND SURVIVAL FOLLOWING CONCOMITANT CHEMORADIOTHERAPY IN INOPERABLE STAGE I NON-SMALL-CELL LUNG CANCER
Marie-Pierre Campeau, Alan Herschtal, Greg Wheeler, Michael Mac Manus, Andrew Wirth, Michael Michael, Annette Hogg, Elizabeth Drummond, David Ball
Journal article | 2009 | International Journal of Radiation Oncology*Biology*Physics
Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation.
Daniel L Worthley, Andrew Ruszkiewicz, Ruth Davies, Sarah Moore, Ian Nivison-Smith, L Bik To, Peter Browett, Robyn Western, Simon Durrant, Jason So, Graeme P Young, Charles G Mullighan, Peter G Bardy, Michael Z Michael
Journal article | 2009 | Stem Cells
This study characterized the contribution of bone marrow-derived cells to human neoplasia and the perineoplastic stroma. The Austr..
The Lewis-Y Carbohydrate Antigen is Expressed by Many Human Tumors and Can Serve as a Target for Genetically Redirected T cells Despite the Presence of Soluble Antigen in Serum
Jennifer A Westwood, William K Murray, Melanie Trivett, Nicole M Haynes, Benjamin Solomon, Linda Mileshkin, David Ball, Michael Michael, Angela Burman, Preethi Mayura-Guru, Joseph A Trapani, Stefan Peinert, Dirk Honemann, H Miles Prince, Andrew M Scott, Mark J Smyth, Phillip K Darcy, Michael H Kershaw
Journal article | 2009 | Journal of Immunotherapy
Impact of gastro-esophageal reflux on mucin mRNA expression in the esophageal mucosa.
Aafke HC van Roon, George C Mayne, Bas PL Wijnhoven, David I Watson, Mary P Leong, Gabriëlle E Neijman, Michael Z Michael, Andrew R McKay, David Astill, Damian J Hussey
Journal article | 2008 | Journal of Gastrointestinal Surgery
INTRODUCTION: Changes in the expression of mucin genes in the esophageal mucosa associated with uncomplicated gastro-esophageal re..
Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey.
Kathryn M Field, Suzanne Kosmider, Michael Jefford, Michael Michael, Ross Jennens, Michael Green, Peter Gibbs
Journal article | 2008 | Journal of Oncology Practice
PURPOSE: Determining the optimal starting dose of chemotherapy (CHT) presents a considerable challenge when using body-surface are..
Drug metabolism by tumours: its nature, relevance and therapeutic implications.
Michael Michael, Margaret M Doherty
Journal article | 2007 | Expert Opinion on Drug Metabolism & Toxicology
Drug-metabolising enzymes (DMEs) are present in tumours and are capable of biotransforming a variety of antineoplastics. Tumoural ..
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
D Goldstein, G Van Hazel, E Walpole, C Underhill, D Kotasek, M Michael, J Shapiro, T Davies, W Reece, J Harvey, N Spry
Journal article | 2007 | British Journal of Cancer
The aim of this phase II study was to assess the feasibility and efficacy of a specific three-dimensional conformal radiotherapy t..
Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: Review of a single institution's experience
Michael Ng, Jennifer Chong, Alvin Milner, Michael MacManus, Greg Wheeler, Andrew Wirth, Michael Michael, Vinod Ganju, Joe McKendrick, David Ball
Journal article | 2007 | Journal of Thoracic Oncology
Selective iNOS inhibition enhances spontaneous gallbladder motility in the Australian possum.
CM Woods, P Sandstrom, M Bond, M Michael, J Svanvik, J Toouli, GTP Saccone
Journal article | 2007 | Neurogastroenterology & Motility
Gallbladder inflammation is a common and painful disease. Inducible nitric oxide synthase (iNOS) plays a major role in inflammator..
Relationship of hepatic functional Imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination
Michael Michael, Mick Thompson, Rod J Hicks, Paul L Mitchell, Andrew Ellis, Alvin D Milner, Julia Di Iulio, Andrew M Scott, Volker Gurtler, Janelle M Hoskins, Stephen J Clarke, Niall C Tebbut, Kian Foo, Michael Jefford, John R Zalcberg
Journal article | 2006 | Clinical Oncology
The caudal-related homeodomain protein Cdx2 and hepatocyte nuclear factor 1alpha cooperatively regulate the UDP-glucuronosyltransferase 2B7 gene promoter.
Philip A Gregory, Dione A Gardner-Stephen, Anne Rogers, Michael Z Michael, Peter I Mackenzie
Journal article | 2006 | Pharmacogenetics and Genomics
The gastrointestinal tract, contains several UDP-glucuronosyltransferases (UGTs) of the UGT1A and UGT2B subfamilies. UGT2B7 is one..
Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity
Paul L Mitchell, David Goldstein, Michael Michael, Philip Beale, Michael Friedlander, John Zalcberg, Shane White, Jacquelyn A Thomson, Stephen Clarke
Journal article | 2006 | Clinical Colorectal Cancer
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer
Cuong P Duong, Rodney J Hicks, LeAnn Weih, Elizabeth Drummond, Trevor Leong, Michael Michael, Robert JS Thomas
Journal article | 2006 | European Journal of Nuclear Medicine and Molecular Imaging
Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.
E Ioachim, MC Michael, M Salmas, K Damala, E Tsanou, MM Michael, V Malamou-Mitsi, NE Stavropoulos
Journal article | 2006 | BMC Cancer
BACKGROUND: Thrombospondin-1 (TSP-1) is an extracellular matrix component glycoprotein, which is known to be a potent inhibitor of..
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins.
E Ioachim, M Michael, M Salmas, MM Michael, NE Stavropoulos, V Malamou-Mitsi
Journal article | 2006 | Urologia Internationalis
Hypoxia-inducible factors (HIF-1alpha and HIF-2alpha) are closely related protein complexes that activate transcription of target ..
A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC
M Michael, A Wirth, DL Ball, M MacManus, D Rischin, L Mileshkin, B Solomon, J McKendrick, AD Milner
Journal article | 2005 | British Journal of Cancer
Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients
D Goldstein, P Mitchell, M Michael, P Beale, M Friedlander, J Zalcberg, S White, S Clarke
Journal article | 2005 | British Journal of Cancer
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AN1424) to prevent chemotherapy induced peripheral neuropathy
ID Davis, L Kiers, L MacGregor, M Quinn, J Arezzo, M Green, M Rosenthal, M Chia, M Michael, P Bartley, L Harrison, M Daly
Journal article | 2005 | Clinical Cancer Research
Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial
S Loi, SYK Ngan, RJ Hicks, B Mukesh, P Mitchell, M Michael, J Zalcberg, T Leong, D Lim-Joon, J Mackay, D Rischin
Journal article | 2005 | British Journal of Cancer
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
Michael Michael, MaryAnne Brittain, Jane Nagai, Ronald Feld, David Hedley, Amit Oza, Lillian Siu, Malcolm J Moore
Journal article | 2004 | Journal of Clinical Oncology
PURPOSE: The dose-limiting toxicity of irinotecan (CPT-11; Camptosar) is delayed-onset diarrhea, with an incidence at the grade 3 ..
Implications of dose rounding of chemotherapy to the nearest vial size.
Michael Joseph Dooley, Sanjay Singh, Michael Michael
Journal article | 2004 | Supportive Care in Cancer
GOALS OF WORK: There are practical implications of preparing cytotoxic doses calculated to the exact milligram. The objective here..
Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer
B Solomon, DL Ball, G Richardson, JG Smith, M Millward, M MacManus, M Michael, A Wirth, C O'Kane, L Muceniekas, G Ryan, D Rischin
Journal article | 2003 | Lung Cancer
Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells.
Michael S Michael, Mostafa Z Badr, Alaa F Badawi
Journal article | 2003 | International journal of molecular medicine
Cyclooxygenase-2 (COX-2) expression and peroxisome proliferator-activated receptor-gamma (PPARgamma) inactivation are linked to in..
Prognostic significance of the deleted in colorectal cancer gene protein expression in high-risk resected gastric carcinoma.
Aristotle T Bamias, Maria C Bai, Niki J Agnantis, Michael C Michael, Yiannis P Alamanos, Stella V Stefanaki, Evagelia D Razi, Dimosthenis V Skarlos, Angelos M Kappas, Nicholas A Pavlidis
Journal article | 2003 | Cancer Investigation
The deleted in colorectal cancer (DCC) gene is a candidate tumor suppressor gene that may be associated with differentiation and p..
Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.
Fiona H Blackhall, Melania Pintilie, Michael Michael, Natasha Leighl, Ronald Feld, Ming-Sound Tsao, Frances A Shepherd
Journal article | 2003 | Clinical Cancer Research
PURPOSE: The Kit receptor has been proposed as a key molecular target for the treatment of small cell lung cancer (SCLC). Protein ..
FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy - Survival correlates with metastatic disease burden
MP MacManus, R Hicks, R Fisher, D Rischin, M Michael, A Wirth, DL Ball
Journal article | 2003 | Acta Oncologica
Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer.
Alaa F Badawi, Samy L Habib, Mohammed A Mohammed, Ahmed A Abadi, Michael S Michael
Journal article | 2002 | Cancer Investigation
The present study examines the effect of tobacco smoking on the expression of cyclooxygenase (COX)-2 gene, COX enzymatic activity ..
Tumor markers in stage P1 bladder cancer.
NE Stavropoulos, E Ioachim, A Charchanti, MC Michael, E Kitsiou, I Mihailidis, K Hastazeris, NJ Agnantis
Journal article | 2001 | Anticancer Research
BACKGROUND: The infiltration of muscularis mucosa in superficial bladder cancer has been reported to be predictive of an unfavoura..
Risk factors for hepatocellular carcinoma in Egypt: the role of hepatitis-B viral infection and schistosomiasis.
AF Badawi, MS Michael
Journal article | 1999 | Anticancer Research
Hepatitis-B viral (HBV) infection and schistosomiasis are among the most common causes of liver cancer (hepatocellular carcinoma; ..
Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer.
M Michael, B Babic, R Khokha, M Tsao, J Ho, M Pintilie, K Leco, D Chamberlain, FA Shepherd
Journal article | 1999 | Journal of Clinical Oncology
PURPOSE: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are important in tumor development and progression. ..
Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment.
M Michael, IF Tannock
Journal article | 1998 | CMAJ
Quality of life is a subjective multidimentional concept that can be assessed by means of validated questionnaires completed by pa..
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
LL Siu, AM Oza, EA Eisenhauer, PS Firby, JJ Thiessen, M Michael, N Wainman, J Manzo, R Feld, RA Goldberg, MJ Moore
Journal article | 1998 | Journal of Clinical Oncology
PURPOSE: 9-Aminocamptothecin (9-AC) is a water-insoluble camptothecin (CMP) derivative that inhibits normal topoisomerase I functi..
Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer.
M Michael, GC Toner, IN Olver, A Fenessy, JF Bishop
Journal article | 1997 | American Journal of Clinical Oncology
This study investigated dose intensification of epirubicin administered as a 2-weekly regimen with granulocyte-macrophage colony-s..
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
JD Shapiro, MJ Millward, D Rischin, JD Davison, M Michael, PA Francis, V Ganju, GC Toner
Journal article | 1997 | Australian and New Zealand Journal of Medicine
BACKGROUND: Metastatic breast cancer is a major cause of cancer death in Australian women. Docetaxel is a new cytotoxic drug that ..
Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.
JD Shapiro, MJ Millward, D Rischin, M Michael, V Walcher, PA Francis, GC Toner
Journal article | 1996 | Gynecologic Oncology
Thirty-eight women with epithelial ovarian cancer were treated with gemcitabine, a new antimetabolite. All had previously received..
Association of acquired Pelger-Huet anomaly with taxoid therapy.
SK Juneja, JP Matthews, R Luzinat, Y Fan, M Michael, D Rischin, MJ Millward, GC Toner
Journal article | 1996 | British Journal of Haematology
We describe the occurrence of acquired Pelger-Huet anomaly (APHA) in 23 patients treated with paclitaxel (13) or docetaxel (10). A..
The immunogenicity of MUC1 peptides and fusion protein.
V Apostolopoulos, GA Pietersz, PX Xing, CJ Lees, M Michael, J Bishop, IF McKenzie
Journal article | 1995 | Cancer Letters
Mucin 1 (MUC1) is highly expressed in breast cancer, has an ubiquitous distribution and, due to altered glycosylation, peptides wi..
Honours, Awards and Fellowships
FRACP - Fellow of the Royal Australasian College of Physicians
Medicine - St Vincent'S Hospital
The Sir Peter Maccallum Department Of Oncology
Bachelor of Science (Honours)
University of Melbourne
Bachelor of Medicine
Bachelor of Surgery
Doctorate of Medicine
University of Melbourne